Farzaneh Rahmani1, Amene Saghazadeh2, Maryam Rahmani3, Antonio L Teixeira4, Nima Rezaei5, Vajiheh Aghamollaii6, Hassan Eftekhar Ardebili7. 1. Students Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran; NeuroImaging Network (NIN), Universal Scientific Education and Research Network (USERN), Tehran, Iran. 2. Systematic Review and Meta-analysis Expert Group (SRMEG), Universal Scientific Education and Research Network (USERN), Tehran, Iran. 3. Students Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran. 4. Department of Psychiatry and Behavioral Sciences, The University of Texas Health Science Center at Houston, Houston, TX, USA; Laboratório Interdisciplinar de Investigação Médica, Faculdade de Medicina, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil. 5. NeuroImaging Network (NIN), Universal Scientific Education and Research Network (USERN), Boston, USA; Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran; Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. 6. Department of Neurology, Roozbeh Hospital, Tehran University of Medical Sciences, Roozbeh Hospital, Tehran, Iran. Electronic address: V-aghamollaii@sina.tums.ac.ir. 7. Department of Health Education and Promotion, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: eftkhara@tums.ac.ir.
Abstract
BACKGROUND: Brain-derived neurotrophic factor (BDNF) is an abundant neurotrophin in the adult brain. Serum BDNF levels might be used as a proxy for its central expression. Considering conflicting reports, we aimed to answer "How do serum/CSF levels of BDNF change in patients with PD?". METHODS: We conducted a comprehensive search in MEDLINE, EMBASE and SCOPUS databases including 12 eligible studies. Five studies compared BDNF in serum of PD patients versus healthy controls (HC) and 3 studies provided BDNF levels in sera of non-depressed and depressed PD patients (NDPD and DPD). Review Manager and Software version 3.0 were used for meta-analysis and meta-regressions. Mean difference (MD) was used for measurement of effect size. RESULTS: PD patients had reduced serum BDNF levels compared to HC (MD = -2.99 ng/mL). Serum BDNF was highest in DPD patients compared to HC (MD = -4.83 ng/mL), with no difference between DPD and NDPD patients in serum BDNF levels. Among co-variates that were eligible for meta-regression, age, sex, and Hoehn and Yahr (H&Y) motor stage had significant positive associations with the effect size in the difference of serum BDNF between patients and HC. CONCLUSIONS: PD patients had reduced serum BDNF levels compared to HC, regardless of presence of co-morbid depression. PD is at least equally effective in reducing serum BDNF levels as depression. Motor progression predicts serum BDNF downregulation in PD. Acute exercise improves motor function and depressive symptoms in PD probably via BDNF upregulation. The paradoxical rise in serum BDNF in advance PD is probably compensatory in nature.
BACKGROUND:Brain-derived neurotrophic factor (BDNF) is an abundant neurotrophin in the adult brain. Serum BDNF levels might be used as a proxy for its central expression. Considering conflicting reports, we aimed to answer "How do serum/CSF levels of BDNF change in patients with PD?". METHODS: We conducted a comprehensive search in MEDLINE, EMBASE and SCOPUS databases including 12 eligible studies. Five studies compared BDNF in serum of PDpatients versus healthy controls (HC) and 3 studies provided BDNF levels in sera of non-depressed and depressed PDpatients (NDPD and DPD). Review Manager and Software version 3.0 were used for meta-analysis and meta-regressions. Mean difference (MD) was used for measurement of effect size. RESULTS:PDpatients had reduced serum BDNF levels compared to HC (MD = -2.99 ng/mL). Serum BDNF was highest in DPDpatients compared to HC (MD = -4.83 ng/mL), with no difference between DPD and NDPD patients in serum BDNF levels. Among co-variates that were eligible for meta-regression, age, sex, and Hoehn and Yahr (H&Y) motor stage had significant positive associations with the effect size in the difference of serum BDNF between patients and HC. CONCLUSIONS:PDpatients had reduced serum BDNF levels compared to HC, regardless of presence of co-morbid depression. PD is at least equally effective in reducing serum BDNF levels as depression. Motor progression predicts serum BDNF downregulation in PD. Acute exercise improves motor function and depressive symptoms in PD probably via BDNF upregulation. The paradoxical rise in serum BDNF in advance PD is probably compensatory in nature.
Authors: Mohammad Malekan; Sasan Salehi Nezamabadi; Elham Samami; Mehdi Mohebalizadeh; Amene Saghazadeh; Nima Rezaei Journal: J Cancer Res Clin Oncol Date: 2022-09-29 Impact factor: 4.322
Authors: Smrithi Padmakumar; Gregory Jones; Grishma Pawar; Olga Khorkova; Jane Hsiao; Jonghan Kim; Mansoor M Amiji; Benjamin S Bleier Journal: J Control Release Date: 2021-01-21 Impact factor: 9.776
Authors: Catherine Madurski; Jessica M Jarvis; Sue R Beers; Amy J Houtrow; Amy K Wagner; Anthony Fabio; Chunyan Wang; Craig M Smith; Lesley Doughty; Keri Janesko-Feldman; Pamela Rubin; Dorothy Pollon; Amery Treble-Barna; Patrick M Kochanek; Ericka L Fink Journal: Neurocrit Care Date: 2021-03-04 Impact factor: 3.532
Authors: Aeja Jackson; Christopher B Forsyth; Maliha Shaikh; Robin M Voigt; Phillip A Engen; Vivian Ramirez; Ali Keshavarzian Journal: Front Neurol Date: 2019-12-10 Impact factor: 4.003
Authors: Steven Paul Woods; Michelle Babicz; Lokesh Shahani; Gabriela Delevati Colpo; Erin E Morgan; Antonio L Teixeira Journal: J Neurovirol Date: 2020-11-03 Impact factor: 2.643